Analysts Have Conflicting Sentiments on These Healthcare Companies: Revvity (RVTY), PTC Therapeutics (PTCT) and Tectonic Therapeutic (TECX)
Baird Adjusts Price Target on Revvity to $136 From $127
A Quick Look at Today's Ratings for Revvity(RVTY.US), With a Forecast Between $125 to $145
Revvity Price Target Raised to $125.00/Share From $115.00 by Barclays
Revvity's Balanced Performance Amidst Market Challenges: A Hold Recommendation With Updated Price Objective
Barclays Sticks to Their Hold Rating for Revvity (RVTY)
Revvity Analyst Ratings
Nephron Adjusts Price Target on Revvity to $134 From $124
Revvity Analyst Ratings
Revvity Analyst Ratings
Barclays Trims Price Target on Revvity to $115 From $116
Revvity Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), DocGo (DCGO) and Revvity (RVTY)
Bernstein Adjusts Price Target on Revvity to $123 From $125, Keeps Outperform Rating
Revvity (RVTY) Receives a Hold From Barclays
Nephron Adjusts Revvity's Price Target to $124 From $120
Barclays Keeps Their Hold Rating on Revvity (RVTY)
Raymond James Maintains Outperform on Revvity, Raises Price Target to $127
Revvity Analyst Ratings
Analysts Conflicted on These Healthcare Names: Exelixis (EXEL), Revvity (RVTY) and Becton Dickinson (BDX)